Investors continue to assess tariff risks after heavy sell-off last weekRead More
You might also be interested in reading Merck wins EU nod for Welireg against two kidney cancer indications.
Investors continue to assess tariff risks after heavy sell-off last weekRead More
You might also be interested in reading Merck wins EU nod for Welireg against two kidney cancer indications.